We are pioneering a metabolism-based liquid biopsy. Our mission is to prevent cancer mortality through early detection.
We measure the GAGome — system biomarkers of tumor metabolism — then use machine learning to detect signatures of cancer noninvasively.
We welcome partnerships with academia to explore clinical applications as well as industry for the development of companion diagnostics.
We welcome interest from investors and are happy to provide more information on our plans on request.
We are always looking to interact with top talents interested in joining our development team.
Elypta AB, Nanna Svartz väg 4, 171 65 Solna, Sweden